SREBF2 and metabolic dysfunction-associated steatohepatitis: We hypothesized that intravenous NPC2 administration would mobilize compartmentalized excess cholesterol trapped in hepatic cells within LE/LY compartments through SREBP2-pathway controlled alterations in gene expression, thereby ameliorating NASH changes.